Predictive biomarker of cetuximab response incolorectal cancer patients
Posted in the Oncology Forum
#1 Feb 22, 2012
According to a recent US patent application, serum YKL-40 can be a prognostic biomarker for predicting short overall survival in patients with metastatic colorectal cancer treated with cetuximab. Details: http://www.sciclips.com/sciclips/biomarker-ne...
Add your comments below
|New Drug Shows Potential for Blood Cancer||Jun 16||Johnwillton||2|
|$20M cancer center opens today in Clifton Park||Jun 5||Dennis S||1|
|Researchers hail new cancer treatment that unlo...||Jun '15||Hypothetical||1|
|CTCA Oncologist Discusses Cancer Risks Among Mi...||May '15||Ms Louisiana||1|
|Risk of a calamity if North haze not tackled ur...||Apr '15||norman||1|
|To Your Good Health: Mental health doctors impo...||Apr '15||HumanSpirit||2|
|To battle cancer, choose oncologist with care (May '08)||Apr '15||VoteJoe||31|
Find what you want!
Search Oncology Forum Now
Copyright © 2015 Topix LLC